ONE VECTOR SYSTEM FOR IDENTIFICATION OF GENOME MODIFYING ENZYMES
The present application relates to an integrated one vector system for identifying a genome modifying enzyme, e.g., from a large library. The one-vector system integrates the components for enzyme identification into a single vector to facilitate a high throughput screening process.
1 . A method for identifying a genome modifying enzyme using a one-vector system, wherein the one vector system comprises a vector comprising a nucleotide sequence encoding a genome modifying enzyme, a target site sequence that is recognizable by the genome modifying enzyme, and a unique identifier that correlates to the genome modifying enzyme.
2 . The method of claim 1 , wherein the genome modifying enzyme includes serine recombinase (e.g., large and small serine recombinases), tyrosine recombinase (e.g., Flp, λ-integrase, and Dre), retrotransposon (e.g., LTRs, LINEs and SINEs), DNA transposase, nuclease, chimeric genome modifying enzyme, and the like.
3 . The method of claim 1 or 2 , wherein the target site sequence is a native target site sequence, or an engineered target site sequence that is recognizable by the genome modifying enzyme in the same vector.
4 . The method of any one of the preceding claims , wherein the unique identifier comprises a nucleotide sequence of about 5-30, 5-20, 8-30, 8-20, 10-30, or 10-20 nucleotides in length.
5 . The method of any one of the preceding claims , wherein the unique identifier comprises a nucleotide sequence of about 20 nucleotides in length.
6 . The method of any one of the preceding claims , wherein the vector further comprises a reporter.
7 . The method of claim 6 , wherein the reporter is a fluorescent protein or a variant thereof.
8 . The method of claim 7 , wherein the reporter is a green fluorescent protein (GFP) or a variant thereof.
9 . The method of any one of the preceding claims , wherein the vector comprises a promoter sequence.
10 . The method of claim 9 , wherein the promoter is a constitutive or inducible.
11 . The method of any one of the preceding claims , wherein the vector further comprises a selective marker.
12 . The method of claim 11 , wherein the selective biomarker is an antibiotic resistance gene (e.g., Puromycin).
13 . The method of any one of the preceding claims , wherein the vector is a non-viral vector.
14 . The method of claim 13 , wherein the non-viral vector is a plasmid, a cosmid, an artificial chromosome vector, or the like.
15 . The method of any one of claims 1-12 , wherein the vector is a viral vector.
16 . The method of claim 15 , wherein the viral vector is an adeno-associated virus (AAV) based vector, an adenovirus based vector, a retrovirus based vector, a lentivirus based vector, a herpesviral vector, a rabies viral vector, or the like.
17 . The method of any one of the preceding claims , wherein the genome modifying enzyme is a serine recombinase.
18 . The method of claim 17 , wherein the serine recombinase is a large serine recombinase (LSR).
19 . The method of claim 18 , wherein the LSR is from a bacteriophage.
20 . The method of claim 18 or 19 , wherein the target site sequence comprises an attP recognition site sequence that is derived from a sequence with about 200-300 bps downstream of the coding sequence of the LSR in the phage genome.
21 . The method of claim 18 or 19 , wherein the target site sequence comprises an attP recognition site sequence that is derived from a sequence with about 200-300 bps upstream of the coding sequence of the LSR in the phage genome.
22 . The method of claim 18 or 19 , wherein the target site sequence comprises a pseudo attP recognition site sequence that is recognizable by the LSR.
23 . The method of claim 18 or 19 , wherein the target site sequence comprises a corresponding attB recognition site sequence or a pseudo attB recognition site sequence that is recognizable by the LSR in the vector.
24 . The method of any one of claims 19-23 , wherein the recognition site sequence comprises about 30-75 nucleotides.
25 . A method for identify a genome modifying enzyme for genome modification comprising:
i) transfecting into cells a plurality of vectors, each of which comprises a nucleotide sequence encoding a unique genome modifying enzyme, a target site sequence that is recognizable by the unique genome modifying enzyme in the vector and a unique identifier that correlates to the genome modifying enzyme in the vector;
ii) detecting genome modification activities in the transfected cells; and
iii) identifying the genome modifying enzyme by identifying the unique identifier in the transfected cells in which the genome modification activities are detected.
26 . The method of claim 25 , wherein the genome modification activities are detected about 2 days, 3 days, 5 days, 1 week, or 2 weeks after transfection.
27 . The method of claim 25 or 26 , wherein the genome modification is detected by next-generation sequencing (NGS).
28 . The method of any one of claims 25-27 , wherein the cells are mammalian cells.
29 . The method of claim 28 , wherein the cells are human cells.
30 . The method of any one of claims 25-29 , wherein the unique identifier in each vector comprises a nucleotide sequence of about 5-30, 5-20, 8-30, 8-20, 10-30, or 10-20 nucleotides in length.
31 . The method of claim 30 , wherein the unique identifier comprises a nucleotide sequence of about 20 nucleotides in length.
32 . The method of any one of claims 25-31 , wherein the target site sequence is a native target site sequence, or an engineered target site sequence that is recognizable by the genome modifying enzyme in the same vector.
33 . The method of any one of claims 25-32 , wherein the vector further comprises a reporter.
34 . The method of claim 33 , wherein the reporter is a fluorescent protein, or a variant thereof.
35 . The method of any one of claims 25-34 , wherein the vector comprises a promoter sequence.
36 . The method of claim 35 , wherein the promoter is a constitutive or inducible.
37 . The method of any one of claims 25-36 , wherein the vector further comprises a selective marker.
38 . The method of claim 37 , wherein the selective marker is an antibiotic resistance gene (e.g., Puromycin).
39 . The method of any one of claims 25-38 , wherein the vector is a non-viral vector, or a viral vector.
40 . The method of claim 39 , wherein the vector is a non-viral vector selected from plasmid, cosmid, artificial chromosome vector and the like.
41 . The method of claim 39 , wherein the vector is a viral vector selected from the group consisting of adeno-associated viral vector, adenoviral vector, retroviral vector, lentiviral vector, herpesviral vector, rabies viral vector and the like.
42 . The method of any one of claims 25-41 , wherein the genome modifying enzyme includes serine recombinase (e.g., large and small serine recombinases), tyrosine recombinase (e.g., Flp, λ-integrase, and Dre), retrotransposon, DNA transposase, and the like.
43 . The method of claim 42 , wherein the genome modifying enzyme is a serine recombinase.
44 . The method of claim 43 , wherein the serine recombinase is a large serine recombinase (LSR)
45 . The method of claim 44 , wherein the LSR is from a bacteriophage.
46 . The method of claim 44 or 45 , wherein the target site sequence comprises an attP recognition site sequence that is derived from a sequence with about 200-300 bps downstream of the coding sequence of the LSR in the phage genome.
47 . The method of claim 44 or 45 , wherein the target site sequence comprises an attP recognition site sequence that is derived from a sequence with about 200-300 bps upstream of the coding sequence of the LSR in the phage genome.
48 . The method of claim 44 or 45 , wherein the target site sequence comprises a pseudo attP recognition site sequence that is recognizable by the LSR.
49 . The method of any one of claims 46-48 , wherein the cells comprise a corresponding attB recognition site sequence, or a pseudo-attB recognition sequence that is recognizable by the LSR.
50 . The method of claim 44 or 45 , wherein the target site sequence in the vector comprises a corresponding attB recognition site sequence that is recognizable by the LSR.
51 . The method of claim 44 or 45 , wherein the target site sequence in the vector comprises a pseudo-attB recognition sequence that is recognizable by the LSR.
52 . The method of claim 50 or 51 , wherein the cells comprise a corresponding attP recognition site sequence, or a pseudo-attP recognition sequence that is recognizable by the LSR
53 . A one vector system for identifying a genome modifying enzyme, wherein the vector comprises a nucleotide sequence encoding a genome modifying enzyme, a target site sequence that is recognizable by the genome modifying enzyme in the vector and a unique identifier that correlates to the genome modifying enzyme in the vector.
54 . The one vector system of claim 53 , wherein the vector further comprises a reporter gene.
55 . The one vector system of claim 53 or 54 , wherein the vector comprises a promoter sequence.
56 . The one vector system of any one of claims 53-55 , wherein the unique identifier comprises a nucleotide sequence of about 5-30, 5-20, 8-30, 8-20, 10-30, or 10-20 nucleotides in length.
57 . The one vector system of any one of claims 53-56 , wherein the vector comprises a selection marker.
58 . The one vector system of any one of claims 53-57 , wherein the system comprises a plurality of vectors, each of which comprises a nucleotide sequence encoding a unique genome modifying enzyme, a target site sequence that is recognizable by the unique genome modifying enzyme in the same vector and a unique identifier that correlates to the genome modifying enzyme in the same vector.
59 . A method for identifying a recognition site sequence for a recombinase using a one vector system wherein the method comprising,
i) transfecting into cells a plurality of vectors, each of which comprises a nucleotide sequence encoding the recombinase and a unique recognition site sequence and a unique identifier that correlates to the unique recognition site sequence;
ii) detecting recombination activity in the transfected cells; and
iii) identifying the recognition site sequence by identifying the unique identifier in the transfected cells in which the recombination activity is detected.
60 . The method of claim 59 , wherein the recombinase is a large serine recombinase (LSR).
61 . The method of claim 60 , wherein the recognition site is an attP site sequence, or an attB site sequence.
62 . The method of claim 61 , wherein the recognition site sequence is a mutated attP site sequence or a mutated attB site sequence.